Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study

Summary Background The advent of targeted therapies in the past 7 years has extended median survival for metastatic renal-cell carcinoma. This improvement in clinical outcome has created a need for new, more accurate prognostic measures. We assessed the use of conditional survival—a measure that acc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2012-09, Vol.13 (9), p.927-935
Hauptverfasser:	Harshman, Lauren C, MD, Xie, Wanling, MS, Bjarnason, Georg A, MD, Knox, Jennifer J, MD, MacKenzie, Mary, MD, Wood, Lori, MD, Srinivas, Sandy, MD, Vaishampayan, Ulka N, MD, Tan, Min-Han, MD, Rha, Sun-Young, Prof, Donskov, Frede, MD, Agarwal, Neeraj, MD, Kollmannsberger, Christian, MD, North, Scott, MD, Rini, Brian I, Prof, Heng, Daniel YC, MD, Choueiri, Toni K, Dr
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - mortality Carcinoma, Renal Cell - secondary Female Follow-Up Studies Hematology, Oncology and Palliative Medicine Humans Kaplan-Meier Estimate Kidney Neoplasms - drug therapy Kidney Neoplasms - mortality Male Metastasis Middle Aged Prognosis Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!